Abemaciclib

Active ingredient description

Abemaciclib is a potent and selective inhibitor of cyclin-dependent kinases 4 and 6 (CDK4 and CDK6), and most active against Cyclin D1/CDK4 in enzymatic assays. Abemaciclib prevents retinoblastoma protein (Rb) phosphorylation, blocking cell cycle progression from the G1 to the S-phase of cell division, leading to suppression of tumour growth.

Medicine classification

This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:

ATC code
Group title
Classification
L01EF03
L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01E Protein kinase inhibitors → L01EF Cyclin-dependent kinase (CDK) inhibitors
Discover more medicines within L01EF03

Medicines

Abemaciclib is the active ingredient of these drugs:

Drug
Countries
VERZENIO

Australia Canada Ecuador Hong Kong Singapore

VERZENIOS

Austria Brazil Cyprus Estonia Finland

Product monographs

Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):

Title
Type
Country
VERZENIOS Film-coated tablet
Summary of Product Characteristics (SPC)

Structural formula

Graphic representation of the active ingredient's molecular structure

Molecular mass: 506.606 g/mol

External identifiers

CAS Substance: 1231929-97-7
DrugBank Drug: DB12001
RxNorm Ingredient: 1946825
SNOMED-CT Concept: 761851004
Abemaciclib (substance)
UNII Identifier: 60UAB198HK
ABEMACICLIB
 
Next: Usage >